[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA40580A - Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques - Google Patents

Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Info

Publication number
MA40580A
MA40580A MA040580A MA40580A MA40580A MA 40580 A MA40580 A MA 40580A MA 040580 A MA040580 A MA 040580A MA 40580 A MA40580 A MA 40580A MA 40580 A MA40580 A MA 40580A
Authority
MA
Morocco
Prior art keywords
integrin
antagonists
beta
alpha
treatment
Prior art date
Application number
MA040580A
Other languages
English (en)
Other versions
MA40580B1 (fr
Inventor
Niall Andrew Anderson
Matthew Howard James Campbell-Crawford
Ashley Paul Hancock
John Martin Pritchard
Joanna Mary Redmond
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of MA40580A publication Critical patent/MA40580A/fr
Publication of MA40580B1 publication Critical patent/MA40580B1/fr

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'invention concerne un composé de formule (i), ce dernier étant un acide 4-(3-fluoro-3-(2-(5, 6, 7, 8-tétrahydro-l, 8-naphthyridin-2-yl) éthyl) pyrrolidin-l-yl)-3-(3-(2-méthoxyéthoxy) phényl) butanoïque, ou un sel de ce dernier.
MA40580A 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques MA40580B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1417002.1A GB201417002D0 (en) 2014-09-26 2014-09-26 Novel compound
EP15767475.5A EP3197892B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques
PCT/EP2015/071776 WO2016046225A1 (fr) 2014-09-26 2015-09-22 Nouveaux composés

Publications (2)

Publication Number Publication Date
MA40580A true MA40580A (fr) 2017-08-02
MA40580B1 MA40580B1 (fr) 2018-09-28

Family

ID=51901158

Family Applications (1)

Application Number Title Priority Date Filing Date
MA40580A MA40580B1 (fr) 2014-09-26 2015-09-22 Derives de naphthyridine en tant qu'antagonistes d'alpha v beta 6 integrin pour le traitement des troubles fibrotiques

Country Status (36)

Country Link
US (3) US9956209B2 (fr)
EP (2) EP3428167A1 (fr)
JP (1) JP6611799B2 (fr)
KR (1) KR101998000B1 (fr)
CN (1) CN107074848B (fr)
AR (1) AR101994A1 (fr)
AU (1) AU2015320858B2 (fr)
BR (1) BR112017006251A2 (fr)
CA (1) CA2962315A1 (fr)
CL (1) CL2017000705A1 (fr)
CO (1) CO2017002714A2 (fr)
CR (1) CR20170112A (fr)
CY (1) CY1121071T1 (fr)
DK (1) DK3197892T3 (fr)
DO (1) DOP2017000081A (fr)
EA (1) EA031481B1 (fr)
ES (1) ES2690748T3 (fr)
GB (1) GB201417002D0 (fr)
HR (1) HRP20181796T1 (fr)
HU (1) HUE041827T2 (fr)
IL (1) IL250592A0 (fr)
JO (1) JO3413B1 (fr)
LT (1) LT3197892T (fr)
MA (1) MA40580B1 (fr)
MX (1) MX2017003948A (fr)
PE (1) PE20170502A1 (fr)
PH (1) PH12017500361A1 (fr)
PL (1) PL3197892T3 (fr)
PT (1) PT3197892T (fr)
RS (1) RS58000B1 (fr)
SG (1) SG11201701183YA (fr)
SI (1) SI3197892T1 (fr)
TW (1) TW201629056A (fr)
UA (1) UA119181C2 (fr)
UY (1) UY36314A (fr)
WO (1) WO2016046225A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201305668D0 (en) 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201604589D0 (en) * 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604681D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
GB201604680D0 (en) * 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds
KR102510858B1 (ko) 2016-11-08 2023-03-15 브리스톨-마이어스 스큅 컴퍼니 알파 v 인테그린 억제제로서의 아졸 아미드 및 아민
EA201991123A1 (ru) 2016-11-08 2019-11-29 ИНДАЗОЛОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ АНТАГОНИСТОВ ИНТЕГРИНА αV
AR110139A1 (es) 2016-11-08 2019-02-27 Bristol Myers Squibb Co COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV
PT3538528T (pt) * 2016-11-08 2021-02-16 Bristol Myers Squibb Co Pirrol amidas como inibidores de integrina v
SI3538525T1 (sl) 2016-11-08 2022-09-30 Bristol-Myers Squibb Company 3-substituirane propionske kisline kot inhibitorji alfa v integrina
WO2018119087A1 (fr) 2016-12-23 2018-06-28 Pliant Therapeutics, Inc. Composés acides aminés et leurs procédés d'utilisation
EP3589627A4 (fr) 2017-02-28 2020-08-05 Morphic Therapeutic, Inc. Inhibiteurs de l'(alpha-v)(bêta-6) intégrine
MA52117A (fr) 2017-02-28 2022-04-06 Morphic Therapeutic Inc Inhibiteurs de l'intégrine (alpha-v) (bêta-6)
EP3596105B1 (fr) * 2017-03-17 2023-12-27 Technische Universität München Ligands de synthèse d'intégrine alpha.v.beta.8 et leurs utilisations
CN111433207B (zh) 2017-11-07 2023-07-25 百时美施贵宝公司 作为αV整合素抑制剂的吡咯并吡嗪衍生物
CN108208177A (zh) * 2017-11-28 2018-06-29 上海交通大学医学院附属新华医院 含丁酸类化合物的组合物及其应用
KR20210065935A (ko) * 2018-08-29 2021-06-04 모픽 테라퓨틱, 인코포레이티드 αvβ6 인테그린 억제
WO2020047208A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutic, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta-6)
WO2020047207A1 (fr) * 2018-08-29 2020-03-05 Morphic Therapeutics, Inc. Inhibiteurs de l'intégrine (alpha-v)(bêta -6)
TWI835840B (zh) * 2018-08-29 2024-03-21 美商莫菲克醫療股份有限公司 αvβ6整合素之抑制劑
JP2022512648A (ja) * 2018-10-09 2022-02-07 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 心筋線維化の処置のためのαV-インテグリン(CD51)阻害剤の使用
CA3119807A1 (fr) * 2018-12-04 2020-06-11 Sumitomo Dainippon Pharma Oncology, Inc. Inhibiteurs de cdk9 et leurs polymorphes destines a etre utilises en tant qu'agents pour le traitement du cancer
GB202010626D0 (en) 2020-07-10 2020-08-26 Univ Nottingham Compound

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU736026B2 (en) 1997-12-17 2001-07-26 Merck & Co., Inc. Integrin receptor antagonists
ID24955A (id) 1997-12-17 2000-08-31 Merck & Co Inc Antagonis-antagonis reseptor integrin
DZ3263A1 (fr) 1999-06-02 2000-12-07 Merck & Co Inc Antagonistes du recepteur de l'alpha v integrine
CA2376077A1 (fr) 1999-06-23 2000-12-28 Merck & Co., Inc. Antagonistes des recepteurs de l'integrine
EP1229910A4 (fr) * 1999-10-04 2003-10-01 Merck & Co Inc Antagonistes des recepteurs d'integrine
PL355011A1 (en) 1999-11-08 2004-03-22 Merck & Co, Inc. Process and intermediates for the preparation of imidazolidinone alpha v integrin antagonists
US6921767B2 (en) 2000-06-15 2005-07-26 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists derivatives
US7119098B2 (en) * 2000-06-15 2006-10-10 Pharmacia Corporation Heteroarylakanoic acids as intergrin receptor antagonists
AU7793501A (en) 2000-07-26 2002-02-05 Merck & Co Inc Alpha v integrin receptor antagonists
AU2001290772A1 (en) 2000-09-14 2002-03-26 Merck And Co., Inc. Alpha v integrin receptor antagonists
AU2002246757B2 (en) 2001-01-03 2006-02-02 Merck & Co., Inc. Methods and compositions for treating periodontal disease
DE10112771A1 (de) 2001-03-16 2002-09-26 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta¶6¶
MY130622A (en) 2001-11-05 2007-07-31 Novartis Ag Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors
PL216223B1 (pl) 2002-03-13 2014-03-31 Biogen Idec Inc Przeciwciało przeciwko integrynom α<sub>v</sub>β<sub>6</sub>, jego fragment wiążący antygen, zawierająca je kompozycja i ich zastosowanie, komórka hybrydoma oraz sposób wykrywania α<sub>v</sub>β<sub>6</sub> in vitro
US20040224986A1 (en) * 2002-08-16 2004-11-11 Bart De Corte Piperidinyl targeting compounds that selectively bind integrins
MXPA05006727A (es) 2002-12-20 2005-09-08 Pharmacia Corp Acidos heteroarilalcanoicos como antagonistas de receptor de integrina.
US6932865B2 (en) 2003-04-11 2005-08-23 Lockheed Martin Corporation System and method of making single-crystal structures through free-form fabrication techniques
RS53151B (en) 2007-03-23 2014-06-30 Amgen Inc. 3-SUBSTITUTED QUINOLINE OR QUINOXALINE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR (PI3K)
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
JP2011500823A (ja) 2007-10-22 2011-01-06 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Pi3キナーゼ阻害物質としてのピリドスルホンアミド誘導体
WO2011111880A1 (fr) 2010-03-08 2011-09-15 주식회사 메디젠텍 Préparation pharmaceutique pour le traitement ou la prévention de maladies dues à l'export nucléaire de gsk3, comprenant un composé inhibant l'export nucléaire de gsk3
GB201305668D0 (en) * 2013-03-28 2013-05-15 Glaxosmithkline Ip Dev Ltd Avs6 Integrin Antagonists
WO2015048819A1 (fr) 2013-09-30 2015-04-02 The Regents Of The University Of California Composés d'intégrine anti-aphavbêta1 et méthodes correspondantes
GB201417002D0 (en) * 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compound
GB201417094D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417011D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201417018D0 (en) 2014-09-26 2014-11-12 Glaxosmithkline Ip Dev Ltd Novel compounds
CA2976634C (fr) 2015-02-19 2023-10-17 Scifluor Life Sciences, Inc Derives d'acide nonanoique tetrahydronaphthyridinyle fluores et leurs utilisations
CA2981371A1 (fr) 2015-03-10 2016-09-15 The Regents Of The University Of California Inhibiteurs anti-integrine alphavbeta1 et methodes d'utilisation associees
GB201604589D0 (en) 2016-03-18 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical compound
GB201604680D0 (en) 2016-03-21 2016-05-04 Glaxosmithkline Ip Dev Ltd Chemical Compounds

Also Published As

Publication number Publication date
PH12017500361B1 (en) 2017-07-17
LT3197892T (lt) 2018-12-10
SI3197892T1 (sl) 2018-12-31
CR20170112A (es) 2017-05-26
UY36314A (es) 2016-04-29
WO2016046225A1 (fr) 2016-03-31
DK3197892T3 (en) 2018-11-26
DOP2017000081A (es) 2017-04-30
PE20170502A1 (es) 2017-04-27
US10342783B2 (en) 2019-07-09
HUE041827T2 (hu) 2019-05-28
PH12017500361A1 (en) 2017-07-17
MX2017003948A (es) 2017-06-26
KR20170055489A (ko) 2017-05-19
GB201417002D0 (en) 2014-11-12
IL250592A0 (en) 2017-04-30
RS58000B1 (sr) 2019-01-31
HRP20181796T1 (hr) 2018-12-28
EP3197892B1 (fr) 2018-09-05
US20190275016A1 (en) 2019-09-12
CL2017000705A1 (es) 2017-11-03
JP2017528507A (ja) 2017-09-28
US20170290817A1 (en) 2017-10-12
BR112017006251A2 (pt) 2017-12-12
CN107074848A (zh) 2017-08-18
EA201790715A1 (ru) 2017-07-31
EP3428167A1 (fr) 2019-01-16
PL3197892T3 (pl) 2019-05-31
PT3197892T (pt) 2018-12-12
US20180271845A1 (en) 2018-09-27
KR101998000B1 (ko) 2019-07-08
TW201629056A (zh) 2016-08-16
EP3197892A1 (fr) 2017-08-02
ES2690748T3 (es) 2018-11-22
SG11201701183YA (en) 2017-04-27
AR101994A1 (es) 2017-01-25
EA031481B1 (ru) 2019-01-31
AU2015320858A1 (en) 2017-03-09
CN107074848B (zh) 2019-11-01
CA2962315A1 (fr) 2016-03-31
CO2017002714A2 (es) 2017-06-30
MA40580B1 (fr) 2018-09-28
US9956209B2 (en) 2018-05-01
JP6611799B2 (ja) 2019-11-27
AU2015320858B2 (en) 2018-10-18
CY1121071T1 (el) 2019-12-11
UA119181C2 (uk) 2019-05-10
JO3413B1 (ar) 2019-10-20

Similar Documents

Publication Publication Date Title
MA40580A (fr) Derives de naphthyridine en tant qu&#39;antagonistes d&#39;alpha v beta 6 integrin pour le traitement des troubles fibrotiques
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
MA53150A (fr) Composés de benzimidazole en tant qu&#39;inhibiteurs de c-kit
EA201892710A1 (ru) Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa
MA35725B1 (fr) Composés pipérazines alkylés en tant qu&#39;inhibiteurs de l&#39;activité btk
MX2016009403A (es) Compuestos heterociclicos.
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
MA40301B1 (fr) Composés indolecarboxamides utiles comme inhibiteurs de kinase
MA52063A (fr) Composés de n-((hét)arylméthyl)hétéroaryle-carboxamides en tant qu&#39;inhibiteurs de la kallicréine plasmatique
TN2017000075A1 (en) Compounds and compositions as raf kinase inhibitors
EA201691997A1 (ru) Производные 2,4-тиазолинидона в лечении расстройств центральной нервной системы
MA40302B1 (fr) Dérivés de carbazole
MX366820B (es) Moduladores de gpr120 del acido biciclo[2.2.2].
PE20161315A1 (es) Compuestos de pirazolona y usos de los mismos
MA38884A1 (fr) Composé de triazolopyridine, compositions et procédés d&#39;utilisation associés
MX362919B (es) Moduladores del receptor acoplado a proteína-g 120 (gpr120) de ácido biciclo-[2.2.1].
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
MX2017015572A (es) Derivados de 2-(1-heteroarilpiperazin-4-il)metil-1-4,-benzodioxano como antagonistas de alfa2c.
WO2017081702A3 (fr) Procédé de préparation d&#39;enzalutamide.
EA201600507A2 (ru) Новое сочетание 3-[(3-{[4-(4-морфолинилметил)-1h-пиррол-2-ил]метилен}-2-оксо-2,3-дигидро-1h-индол-5-ил)метил]-1,3-тиазолидин-2,4-диона и ингибитора тирозинкиназы egfr
MA41311B1 (fr) Peptides antagonistes du cgrp
MA42602B1 (fr) Antagonistes du recepteur cgrp
PL399182A1 (pl) Sposób wytwarzania nilotinibu
MA38973A1 (fr) Aminohétéroaryles benzamides en tant qu&#39;inhibiteurs de kinase
FR3022245B1 (fr) Derives de 3,5-dihydro-2h-pyrazolo[4,3-c]pyridin-3-one et leur utilisation